Researchers are using functionalized nanodiamonds to precisely monitor neuronal activity at the cellular level, enhancing ...

There has been a lot of excitement since the launch. Not only is the drug extremely effective (people lose about 15 percent ...

AC Immune (ACIU) stock shot up 20% Thursday after the company reported positive data from a Phase 2 study of its drug ...

AC Immune SA (ACIU) has released an update. AC Immune SA announced promising interim results from its Phase 2 trial of the ACI-7104.056 ...

To date, no clinically relevant safety issues have been reported other than transient injection site reactions (49%) and ...

University of Sheffield spinout company, Rinri Therapeutics, a company focused on developing new treatments for hearing loss ...

Researchers have developed a simple model system that can be used to break down fibrils -- the cause of numerous disorders including Alzheimer's and Parkinson's disease -- into their constituent ...

In a new study, researchers at McMaster University have identified a potential treatment for Sandhoff and Tay-Sachs ...

Researchers have identified a new target to treat atherosclerosis, a condition where plaque clogs arteries and causes major cardiac issues, including stroke and heart attack.

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

Researchers found that inhibiting the enzyme TYK2 may reduce the harmful accumulation of tau protein in Alzheimer’s disease, ...